地诺单抗医保后的价格

It is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density.

On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. Denosumab was approved for the first time in 27 EU member states, as well as Norway, Iceland, and Liechtenstein.

So, what is the price of denosumab after medical insurance?

In May 2019, denosumab was conditionally approved for marketing in China. However, because it was conditionally approved and it was only on the market for five months, the domestic selling price of this drug cannot be collected.

Fortunately, denosumab produced by Amgen of the United States has been launched in Turkey. The specification is 125mg/1ml tube/box. The price is equivalent to RMB 3,000, which can be said to be high quality and low price. Therefore, more and more patients are choosing denosumab, which is launched in Turkey by Amgen of the United States. For more information about denosumab, you can consult the medical companion at any time!

How to administer denosumab:

1. Give 120 mg by subcutaneous injection into the upper arm, upper thigh, or abdomen once every 4 weeks;

2. Give calcium and vitamin D when necessary to treat or prevent hypocalcemia.

Adverse reactions of denosumab:

The most common adverse reactions (≥25%) in patients with bone metastases from solid tumors were fatigue/asthenia, hypophosphatemia, and nausea.

Common adverse reactions (≥10%) in patients with giant cell tumor of bone include headache, joint pain, nausea, back pain, fatigue, and extremity pain.

Adverse reactions (≥20%) in patients with malignant hypercalcemia include nausea and vomiting, dyspnea, decreased appetite, headache, peripheral edema, anemia, diarrhea, and constipation.